FDA approves Neuralstem Phase II amytrophic lateral sclerosis trial
The dose escalation and safety trial will expand to two centres in Atlanta and Ann Arbor, subject to approval by the Institutional Review Board at each institution. Neuralstem
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.
In pre-clinical asthma models ASM-024 exhibited the capabilities of inhibitory effects on inflammation, bronchoprotection and smooth muscle relaxation. Asmacure founder and chief medical officer Yvon Cormier said the